Citeline Podcasts

The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin

AI, Philips, Healthtech, Future Health Index 2026

Prevention has moved to the centre of UK health policy, with the NHS 10-year plan promising a decisive shift away from treatment. The financial case for getting there is less widely understood. In this episode of the Over the Counter Podcast, HBW Insight's David Ridley speaks to Liz Hampson, life sciences and health innovation advisory partner at Deloitte, about the firm's recent work on the socioeconomic value of prevention. Hampson explains why every pound invested in prevention returns an estimated £9.20, why early intervention pays off most, and how rising out-of-pocket spending risks creating a two-tier system. The conversation also covers the gender health gap in prevention, the underused role of community pharmacy, and Hampson's argument that health literacy is where consumer health companies can make the greatest difference.

Pink Sheet Editor-in-Chief Nielsen Hobbs, Senior Editor Sue Sutter, and Senior Reporter Maaisha Osman discuss the Pentagon's decision to list WuXi Apptec as a “Chinese military company” (0:58), FDA’s latest adverting enforcement letters (13:02), and the agency’s thoughts on the risks and benefits of relying on AI for regulatory activities (21:16).

More on these topics from the Pink Sheet:

Pentagon Chinese Company Designations Resurface Pharma Supply Chain Concerns

https://insights.citeline.com/pink-sheet/compliance/distribution-supply-chain/pentagon-chinese-company-designations-resurface-pharma-supply-chain-concerns-BMG2DWJI4NDA3DD3SYHIWXLTZI/

US Legislation Targets US-China Dealmaking Amid Fears Of Ceding Biotech Leadership

https://insights.citeline.com/pink-sheet/legislation/us-legislation-targets-us-china-dealmaking-amid-fears-of-ceding-biotech-leadership-54FLFUBN7RELHO6WC7RN5OINYY/

BIOSECURE Legal Lifeline Available For Pharma Companies Using WuXi AppTec … For Now

https://insights.citeline.com/pink-sheet/compliance/distribution-supply-chain/biosecure-legal-lifeline-available-for-pharma-companies-using-wuxi-apptec-for-now-KAD42FTHIJAT3AWS6OJMJHFM4M/

Pentagon Cleared WuXi AppTec Once. Now It Is Being Sued for Changing Its Mind.

https://insights.citeline.com/pink-sheet/compliance/manufacturing/pentagon-cleared-wuxi-apptec-once-now-it-is-being-sued-for-changing-its-mind-XVGIQA3LIFEBZAG6AS6EMENHF4/

Recent US FDA Ad/Promo Untitled Letters Citing More Email, Internet Issues, Less DTC TV Spots

https://insights.citeline.com/pink-sheet/compliance/marketing-and-advertising/recent-us-fda-adpromo-untitled-letters-citing-more-email-internet-issues-less-dtc-tv-spots-X2QUB5LZBRCRLNPGOJZJQMEIWU/

Unapproved Uses Safe Harbor Codified In Revised US FDA Payor Communications Guidance

https://insights.citeline.com/pink-sheet/market-access/government-payers/unapproved-uses-safe-harbor-codified-in-revised-us-fda-payor-communications-guidance-GFHTVUWW7NBH3P2MT6GZL5JLJ4/

US FDA Says AI Played Supporting, Summarizing Role In Fast BLA Review

https://insights.citeline.com/pink-sheet/product-reviews/us-fda-says-ai-played-supporting-summarizing-role-in-fast-bla-review-EKFWWY5SGZFVPL6PVKJVHJOVBQ/

Acting CDER Director Warns AI Over-Reliance Will Trigger GMP Violations

https://insights.citeline.com/pink-sheet/advanced-technologies/ai/acting-cder-director-warns-ai-over-reliance-will-trigger-gmp-violations-7UO5KN7SJJBBLPQT7SLT3SWCJI/

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。今回取り上げた記事はこちら：「US Drug Shortages Ease But Discontinuations Surge, Asia Supply Chain Risks Run Deep（邦訳：米国の医薬品不足は緩和も撤退数は増加、アジア由来の深いサプライチェーンリスク）」URL: https://insights.citeline.com/scrip/focus-on-asia/india/us-drug-shortages-ease-but-discontinuations-surge-asia-supply-chain-risks-run-deep-QTQCO6KNOBG25HXMVNV5HX5NM4/「US Tariffs And Manufacturing Concentration: Double-Edged Sword?（邦訳：米国の関税政策と製造の集中は諸刃の剣か？）」URL: https://insights.citeline.com/scrip/focus-on-asia/india/us-tariffs-and-manufacturing-concentration-double-edged-sword-5HPZCB6UY5EWZMK7QGJLJHS7IE/アメリカ薬局方　最新のVML（脆弱性薬品リスト）はこちらhttps://www.usp.org/sites/default/files/usp/document/public-policy/vulnerable-medicines-list-2025.pdf※全文の閲覧には購読（有料）が必要です。世界の製薬ビジネスメディアScrip（スクリップ）とは？https://www.citeline.com/ja-jp/products-services/commercialization/scrip

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年6月12日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 礼来探索Zepbound在自身免疫性疾病中的应用；阿斯利康在心血管风险管理（CVRM）领域推行互联互通战略； 阿斯利康将口服GLP-1药物推进至III期；勃林格殷格翰凭借survodutide致力于实现高质量减重；以及葛兰素史克通过收购Nuvalent扩大其肿瘤学版图。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-LLJSGYAJJ5EO3J5JMQYNNNSCMU/

Audio roundup of selected biopharma industry content from Scrip over the business week ended June 12, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time–Lilly explores Zepbound in autoimmune disorders; AstraZeneca pursues interconnected strategy in CVRM; AstraZeneca moving oral GLP-1 into Phase III; Boehringer pursues quality weight loss with survodutide; and GSK scales oncology ambitions with Nuvalent buy.  

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-LLJSGYAJJ5EO3J5JMQYNNNSCMU/

Story link: https://insights.citeline.com/scrip/leadership/interviews/flagship-eyes-long-term-partnerships-biopharma-ecosystem-growth-in-korea-3IPE7SDKWNBATHEO7C4J5RHOGI/

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年6月5日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: Revolution公司的daraxonrasib在ASCO大会上引发轰动；默克公司（Merck & Co.）阐述其肿瘤学愿景；美国立法者对中美交易感到不满；ADA大会上的肥胖症治疗新挑战；以及2025年大型制药公司CEO薪酬回升。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-UH6HET2LLNGUJBCSJ3UA2KLGCQ/

Audio roundup of selected biopharma industry content from Scrip over the business week ended May 29, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time – can GLP-1s help in cancer; Novartis on its cardiovascular strategy; Lilly’s retatrutide looks promising in obesity; Lilly’s raises cell and gene therapy bet; and the business impact of China’s new data protections.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-QIUHRJ2UTNCIXB4T2CVZPNXG24/